Duncan Bucknell
Intellectual Property Strategy
Livemint reported late last week that the association of innovator pharmaceutical companies in India (‘OPPI‘), has recently reiterated its demand for removal of the pre-grant patent opposition provisions from India’s Patent...
There’s a common strategic issue for generic pharmaceuticla manufacturers as to whether they should obtain a win in court before launching their product. The risks are (a) an injunction and (b)...
Thanks to Patent Docs blog for pointing out that on Monday this week Nucleonics sought en banc review of the CAFC decision which held that it no longer had standing to...
Russia and the USA came first and second in IPKat’s recent poll asking readers to nominate the country in which they would least like to litigate an IP case. (China came...
In an update to the Lipitor Scorecard – mixed success for Ranbaxy in Spain today, but no ealier launch. (This comes after Ranbaxy’s recent success and launch in Norway.) The...
This is the sign on the back of many trucks and buses in Mumbai / Bombay. They’re saying – ‘let me know if you’re there – I don’t want to bump...
Further to my recent post, on Friday 6 July, Warwick Rothnie’s excellent blog (IP War’s) reported a copyright suit brought by a Second Life Resident (Mr Alderman) in relation to products...
On 10 July 2007, the Dublin High Court held that Ranbaxy’s product infringes the Pfizer Base patent.Same result, different country (see the scorecard on this site for details). [Note, though that...
The Carvedilol story took another interesting turn recently, when on 21 June, Teva sued 7 pharmaceutical companies (Dr Reddy’s, Ranbaxy, Lupin, Orchid, Cadilla, USV & Warnbury) for infringement of 4 of...
It’s a common complaint — ok, so why should we bother obtaining that patent / trade mark / design / etc when we will not be able to enforce if a...
You must be logged in to post a comment.